Virusmax has enormous implications for protecting more of the world’s population during a pandemic. The entire annual global flu vaccine production capacity is currently only about 350 million doses. Virusmax can enable manufacturers to at least double the amount of influenza vaccine they produce, reducing dependence on imported supplies.
William Gastle, CEO of Microbix, said: “China is one of the largest countries in the world that does not have domestic manufacturing capacity to supply its population with seasonal and pandemic influenza vaccine and would benefit from having access to this technology.”